Immunohistochemical	O
study	O
of	O
c-fos-positive	B-protein
lymphocytes	I-protein
infiltrated	O
into	O
human	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
during	O
radiation	O
therapy	O
and	O
its	O
clinical	O
significance	O
.	O

C-fos	B-DNA
has	O
been	O
reported	O
to	O
be	O
one	O
of	O
the	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
in	O
signal	O
transduction	O
systems	O
after	O
many	O
kinds	O
of	O
stresses	O
,	O
including	O
ionizing	O
radiation	O
.	O

Changes	O
in	O
c-fos	B-DNA
expression	O
induced	O
by	O
radiation	O
therapy	O
in	O
tumor	O
tissues	O
have	O
not	O
yet	O
been	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
attempted	O
to	O
determine	O
whether	O
c-fos	B-DNA
expression	O
is	O
induced	O
by	O
radiotherapy	O
in	O
human	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
and	O
to	O
establish	O
a	O
possible	O
correlation	O
between	O
c-fos	B-DNA
expression	O
and	O
the	O
therapeutic	O
effects	O
of	O
radiation	O
therapy	O
.	O

Twenty-seven	O
patients	O
with	O
tumors	O
of	O
the	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
and	O
maxillary	O
sinus	O
were	O
examined	O
,	O
all	O
of	O
which	O
were	O
confirmed	O
as	O
squamous	O
cell	O
carcinomas	O
.	O

After	O
obtaining	O
the	O
patients	O
'	O
informed	O
consent	O
,	O
biopsies	O
were	O
performed	O
before	O
treatment	O
and	O
at	O
doses	O
of	O
4	O
,	O
10	O
,	O
and	O
20	O
Gy	O
of	O
radiotherapy	O
,	O
and	O
the	O
specimens	O
were	O
preserved	O
in	O
liquid	O
nitrogen	O
for	O
further	O
examination	O
.	O

Serial	O
sectioning	O
of	O
6	O
micrometer	O
was	O
performed	O
using	O
a	O
cryostat	O
,	O
and	O
samples	O
were	O
immunohistochemically	O
stained	O
using	O
the	O
streptoavidin	B-protein
-biotin	B-protein
peroxidase	I-protein
method	O
and	O
a	O
monoclonal	O
antibody	O
against	O
c-fos	O
.	O

Three	O
of	O
the	O
27	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
showed	O
slight	O
expression	O
of	O
c-fos	O
in	O
their	O
tumor	O
cells	O
before	O
and/or	O
at	O
4	O
or	O
10	O
Gy	O
of	O
radiotherapy	O
.	O

The	O
tumors	O
showed	O
high	O
radiosensitivity	O
.	O

Concerning	O
tumor-infiltrating	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
rate	O
of	O
moderate	O
or	O
remarkable	O
grades	O
of	O
c-fos-positive	B-protein
lymphocytes	I-protein
before	O
radiotherapy	O
and	O
at	O
radiation	O
doses	O
of	O
4	O
,	O
10	O
,	O
and	O
20	O
Gy	O
was	O
8.0	O
,	O
29.2	O
,	O
4.8	O
,	O
and	O
0	O
%	O
,	O
respectively	O
.	O

The	O
relationship	O
between	O
the	O
immunohistochemical	O
findings	O
and	O
the	O
antitumor	O
effect	O
at	O
a	O
radiation	O
dose	O
of	O
20	O
Gy	O
was	O
examined	O
on	O
the	O
corresponding	O
H	O
&	O
E-stained	O
sections	O
.	O

In	O
patients	O
whose	O
infiltration	O
of	O
c-fos-positive	B-protein
lymphocytes	I-protein
into	O
tumor	O
tissues	O
were	O
moderate	O
or	O
remarkable	O
at	O
4	O
Gy	O
of	O
radiotherapy	O
,	O
the	O
tumors	O
responded	O
significantly	O
well	O
to	O
radiation	O
therapy	O
(	O
P	O
<	O
0.025	O
,	O
chi2	O
test	O
)	O
,	O
and	O
the	O
patients	O
took	O
a	O
significantly	O
favorable	O
clinical	O
course	O
(	O
P	O
<	O
0.05	O
,	O
chi2	O
test	O
)	O
.	O

In	O
a	O
sample	O
from	O
one	O
of	O
the	O
patients	O
,	O
c-fos-positive	B-protein
lymphocytes	I-protein
were	O
identified	O
as	O
CD4	O
positive	O
and	O
CD8	O
negative	O
.	O

Therefore	O
,	O
the	O
high	O
radiosensitivity	O
of	O
squamous	O
cell	O
carcinomas	O
in	O
our	O
samples	O
could	O
be	O
explained	O
by	O
an	O
overexpression	O
of	O
c-fos	B-protein
in	O
the	O
tumor-infiltrating	B-cell_type
lymphocytes	I-cell_type
induced	O
by	O
small	O
doses	O
of	O
radiation	O
therapy	O
,	O
and	O
these	O
activated	B-cell_type
lymphocytes	I-cell_type
exerted	O
a	O
cytotoxic	O
effect	O
against	O
the	O
cancer	B-cell_type
cells	I-cell_type
.	O

Vol	NULL
.	NULL

3	NULL
,	NULL
2301-2307	NULL
,	NULL
December	NULL
1997	NULL
Clinical	NULL
Cancer	NULL
Research	NULL
2301	NULL
Immunohistochemical	NULL
Study	NULL
of	NULL
c-fos-positive	NULL
Lymphocytes	NULL
Infiltrated	NULL
into	NULL
Human	NULL
Squamous	NULL
Cell	NULL
Carcinomas	NULL
of	NULL
the	NULL
Head	NULL
and	NULL
Neck	NULL
during	NULL
Radiation	NULL
Therapy	NULL
and	NULL
Its	NULL
Clinical	NULL
Significance	NULL
'	NULL
Yasuhiro	NULL
Ogawa	NULL
,	NULL
``	NULL
Akihito	NULL
Nishioka	NULL
,	NULL
Norihiko	NULL
Hamada	NULL
,	NULL
Masako	NULL
Terashima	NULL
,	NULL
Taisuke	NULL
Inomata	NULL
,	NULL
Shoji	NULL
Yoshida	NULL
,	NULL
Harumichi	NULL
Seguchi	NULL
,	NULL
and	NULL
Seiji	NULL
Kishimoto	NULL
Departments	NULL
of	NULL
Radiology	NULL
[	NULL
Y.	NULL
O.	NULL
,	NULL
A.	NULL
N.	NULL
,	NULL
N.	NULL
H.	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
S	NULL
.	NULL

Y	NULL
.	NULL
]	NULL

,	NULL
Cell	NULL
Biology	NULL
[	NULL
H.	NULL
S.	NULL
]	NULL
,	NULL
and	NULL
Otorhinolaryngology	NULL
[	NULL
S.	NULL
K.	NULL
}	NULL
,	NULL
Kochi	NULL
Medical	NULL
School	NULL
,	NULL
Kochi	NULL
783	NULL
,	NULL
Japan	NULL
ABSTRACT	NULL
C-fos	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
one	NULL
of	NULL
the	NULL
immediate	NULL
early	NULL
genes	NULL
in	NULL
signal	NULL
transduction	NULL
systems	NULL
after	NULL
many	NULL
kinds	NULL
of	NULL
stresses	NULL
,	NULL
including	NULL
ionizing	NULL
radiation	NULL
.	NULL

Changes	NULL
in	NULL
c-fos	NULL
expression	NULL
induced	NULL
by	NULL
radiation	NULL
therapy	NULL
in	NULL
tumor	NULL
tissues	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
reported	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
attempted	NULL
to	NULL
determine	NULL
whether	NULL
c-fos	NULL
expression	NULL
is	NULL
induced	NULL
by	NULL
radiotherapy	NULL
in	NULL
human	NULL
squamous	NULL
cell	NULL
carcinomas	NULL
of	NULL
the	NULL
head	NULL
and	NULL
neck	NULL
and	NULL
to	NULL
establish	NULL
a	NULL
possible	NULL
correlation	NULL
between	NULL
c-fos	NULL
expression	NULL
and	NULL
the	NULL
therapeutic	NULL
effects	NULL
of	NULL
radiation	NULL
therapy	NULL
.	NULL

Twenty-seven	NULL
patients	NULL
with	NULL
tumors	NULL
of	NULL
the	NULL
oral	NULL
cavity	NULL
,	NULL
oro-pharynx	NULL
,	NULL
and	NULL
maxillary	NULL
sinus	NULL
were	NULL
examined	NULL
,	NULL
all	NULL
of	NULL
which	NULL
were	NULL
confirmed	NULL
as	NULL
squamous	NULL
cell	NULL
carcinomas	NULL
.	NULL

After	NULL
obtaining	NULL
the	NULL
patients	NULL
'	NULL
informed	NULL
consent	NULL
,	NULL
biopsies	NULL
were	NULL
performed	NULL
before	NULL
treatment	NULL
and	NULL
at	NULL
doses	NULL
of	NULL
4	NULL
,	NULL
10	NULL
,	NULL
and	NULL
20	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
,	NULL
and	NULL
the	NULL
specimens	NULL
were	NULL
preserved	NULL
in	NULL
liquid	NULL
nitrogen	NULL
for	NULL
further	NULL
examination	NULL
.	NULL

Serial	NULL
sectioning	NULL
of	NULL
6	NULL
um	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
cryostat	NULL
,	NULL
and	NULL
samples	NULL
were	NULL
immunohis-tochemically	NULL
stained	NULL
using	NULL
the	NULL
streptoavidin-biotin	NULL
peroxidase	NULL
method	NULL
and	NULL
a	NULL
monoclonal	NULL
antibody	NULL
against	NULL
c-fos	NULL
.	NULL

Three	NULL
of	NULL
the	NULL
27	NULL
patients	NULL
with	NULL
squamous	NULL
cell	NULL
carcinoma	NULL
showed	NULL
slight	NULL
expression	NULL
of	NULL
c-fos	NULL
in	NULL
their	NULL
tumor	NULL
cells	NULL
before	NULL
and/or	NULL
at	NULL
4	NULL
or	NULL
10	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
.	NULL

The	NULL
tumors	NULL
showed	NULL
high	NULL
radiosensitivity	NULL
,	NULL
Concerning	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
,	NULL
the	NULL
rate	NULL
of	NULL
moderate	NULL
or	NULL
remarkable	NULL
grades	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
before	NULL
radiotherapy	NULL
and	NULL
at	NULL
radiation	NULL
doses	NULL
of	NULL
4	NULL
,	NULL
10	NULL
,	NULL
and	NULL
20	NULL
Gy	NULL
was	NULL
8.0	NULL
,	NULL
29.2	NULL
,	NULL
4.8	NULL
,	NULL
and	NULL
0	NULL
%	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
the	NULL
immunohisto-	NULL
Received	NULL
7/1/97	NULL
;	NULL
revised	NULL
8/28/97	NULL
;	NULL
accepted	NULL
9/15/97	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

'This	NULL
work	NULL
was	NULL
partly	NULL
supported	NULL
by	NULL
Grants-in-Aid	NULL
09255102	NULL
and	NULL
08266104	NULL
from	NULL
the	NULL
Japanese	NULL
Ministry	NULL
of	NULL
Education	NULL
,	NULL
Science	NULL
,	NULL
Sports	NULL
and	NULL
Culture	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
Department	NULL
of	NULL
Radiology	NULL
,	NULL
Kochi	NULL
Medical	NULL
School	NULL
,	NULL
Oko-cho	NULL
,	NULL
Nankoku-shi	NULL
,	NULL
Kochi	NULL
783	NULL
,	NULL
Japan	NULL
.	NULL

Phone	NULL
:	NULL
0888-80-2366	NULL
;	NULL
Fax	NULL
:	NULL
0888-80-2368.	NULL
chemical	NULL
findings	NULL
and	NULL
the	NULL
antitumor	NULL
effect	NULL
at	NULL
a	NULL
radiation	NULL
dose	NULL
of	NULL
20	NULL
Gy	NULL
was	NULL
examined	NULL
on	NULL
the	NULL
corresponding	NULL
H	NULL
&	NULL
E-stained	NULL
sections	NULL
.	NULL

In	NULL
patients	NULL
whose	NULL
infiltration	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
into	NULL
tumor	NULL
tissues	NULL
were	NULL
moderate	NULL
or	NULL
remarkable	NULL
at	NULL
4	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
,	NULL
the	NULL
tumors	NULL
responded	NULL
significantly	NULL
well	NULL
to	NULL
radiation	NULL
therapy	NULL
(	NULL
P	NULL
<	NULL
0.025	NULL
,	NULL
x	NULL
test	NULL
)	NULL
,	NULL
and	NULL
the	NULL
patients	NULL
took	NULL
a	NULL
significantly	NULL
favorable	NULL
clinical	NULL
course	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
,	NULL
x	NULL
test	NULL
)	NULL
.	NULL

In	NULL
a	NULL
sample	NULL
from	NULL
one	NULL
of	NULL
the	NULL
patients	NULL
,	NULL
c-fos-positive	NULL
lymphocytes	NULL
were	NULL
identified	NULL
as	NULL
CD4	NULL
positive	NULL
and	NULL
CD8	NULL
negative	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
high	NULL
radiosensitivity	NULL
of	NULL
squamous	NULL
cell	NULL
carcinomas	NULL
in	NULL
our	NULL
samples	NULL
could	NULL
be	NULL
explained	NULL
by	NULL
an	NULL
overexpression	NULL
of	NULL
c-fos	NULL
in	NULL
the	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
induced	NULL
by	NULL
small	NULL
doses	NULL
of	NULL
radiation	NULL
therapy	NULL
,	NULL
and	NULL
these	NULL
activated	NULL
lymphocytes	NULL
exerted	NULL
a	NULL
cytotoxic	NULL
effect	NULL
against	NULL
the	NULL
cancer	NULL
cells	NULL
.	NULL

INTRODUCTION	NULL
C-fos	NULL
is	NULL
an	NULL
early	NULL
response	NULL
gene	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
which	NULL
is	NULL
induced	NULL
rapidly	NULL
and	NULL
transiently	NULL
by	NULL
growth	NULL
factors	NULL
and	NULL
mitogens	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
gene	NULL
has	NULL
also	NULL
been	NULL
induced	NULL
by	NULL
exposing	NULL
mammalian	NULL
cells	NULL
to	NULL
ionizing	NULL
and	NULL
UV	NULL
irradiation	NULL
(	NULL
2-4	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
expression	NULL
of	NULL
c-fos	NULL
has	NULL
been	NULL
confirmed	NULL
in	NULL
several	NULL
percentages	NULL
of	NULL
squamous	NULL
cell	NULL
carcinomas	NULL
of	NULL
the	NULL
head	NULL
and	NULL
neck	NULL
(	NULL
5	NULL
)	NULL
,	NULL
changes	NULL
in	NULL
c-fos	NULL
expression	NULL
induced	NULL
by	NULL
radiation	NULL
therapy	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
identified	NULL
.	NULL

Vrdoljak	NULL
et	NULL
al	NULL
.	NULL

(	NULL
6	NULL
)	NULL
have	NULL
reported	NULL
that	NULL
doses	NULL
of	NULL
up	NULL
to	NULL
20	NULL
Gy	NULL
have	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
and	NULL
jun-B	NULL
mRNA	NULL
levels	NULL
in	NULL
two	NULL
rat	NULL
brain	NULL
tumor	NULL
cell	NULL
lines	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
rat	NULL
astrocytes	NULL
,	NULL
on	NULL
which	NULL
c-fos	NULL
expression	NULL
was	NULL
induced	NULL
after	NULL
1	NULL
Gy	NULL
of	NULL
X-ray	NULL
irradiation	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
possibility	NULL
that	NULL
c-fos	NULL
expression	NULL
is	NULL
involved	NULL
with	NULL
the	NULL
radiosensitivity	NULL
of	NULL
tumor	NULL
cells	NULL
has	NULL
been	NULL
considered	NULL
to	NULL
be	NULL
relatively	NULL
low	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
studied	NULL
changes	NULL
in	NULL
the	NULL
c-fos	NULL
expression	NULL
of	NULL
tumor	NULL
cells	NULL
and	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
during	NULL
radiation	NULL
therapy	NULL
using	NULL
an	NULL
immunohistochemical	NULL
method	NULL
and	NULL
a	NULL
monoclonal	NULL
antibody	NULL
against	NULL
c-fos	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
c-fos-positive	NULL
lymphocytes	NULL
are	NULL
induced	NULL
by	NULL
small	NULL
doses	NULL
of	NULL
radiotherapy	NULL
in	NULL
some	NULL
types	NULL
of	NULL
tumors	NULL
that	NULL
exhibit	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
radiosensitivity	NULL
.	NULL

Thus	NULL
,	NULL
our	NULL
study	NULL
has	NULL
attempted	NULL
to	NULL
evaluate	NULL
the	NULL
c-fos	NULL
expression	NULL
of	NULL
tumor	NULL
cells	NULL
and/or	NULL
infiltrating	NULL
lymphocytes	NULL
that	NULL
is	NULL
induced	NULL
by	NULL
low-dose	NULL
irradiation	NULL
of	NULL
squamous	NULL
cell	NULL
carcinomas	NULL
of	NULL
the	NULL
head	NULL
and	NULL
neck	NULL
and	NULL
to	NULL
evaluate	NULL
the	NULL
possible	NULL
correlation	NULL
between	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
oncogene	NULL
and	NULL
the	NULL
therapeutic	NULL
effects	NULL
of	NULL
radiation	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
A	NULL
total	NULL
of	NULL
27	NULL
patients	NULL
with	NULL
malignancies	NULL
of	NULL
the	NULL
head	NULL
and	NULL
neck	NULL
regions	NULL
were	NULL
examined	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

After	NULL
obtaining	NULL
the	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1997	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

2302	NULL
c-fos	NULL
Expression	NULL
during	NULL
Radiation	NULL
Therapy	NULL
Table	NULL
1	NULL
-	NULL
Summarized	NULL
data	NULL
of	NULL
patients	NULL
studied	NULL
Case	NULL
Age	NULL
(	NULL
yr	NULL
)	NULL
Sex	NULL
Site	NULL
TNM	NULL
stage	NULL
``	NULL
Histology	NULL
Treatment	NULL
Antitumor	NULL
effect	NULL
Prognosis	NULL
1	NULL
67	NULL
M	NULL
Tongue	NULL
T	NULL
;	NULL
N	NULL
,	NULL
M	NULL
,	NULL
IV	NULL
WDSCC	NULL
``	NULL
__	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
``	NULL
+	NULL
40	NULL
Gy	NULL
Poor	NULL
'	NULL
Dead	NULL
,	NULL
13	NULL
mo	NULL
2	NULL
71	NULL
F	NULL
Tongue	NULL
T	NULL
;	NULL
N	NULL
,	NULL
M	NULL
,	NULL
IV	NULL
wWDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
+	NULL
40	NULL
Gy	NULL
Poor	NULL
Dead	NULL
,	NULL
13	NULL
mo	NULL
3	NULL
71	NULL
M	NULL
Tongue	NULL
T	NULL
;	NULL
N	NULL
,	NULL
M	NULL
,	NULL
IV	NULL
wWDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Poor	NULL
NED	NULL
,	NULL
``	NULL
22	NULL
mo	NULL
4	NULL
52	NULL
M	NULL
Tongue	NULL
TN	NULL
,	NULL
M	NULL
,	NULL
IV	NULL
MDSCC	NULL
'	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
+	NULL
40	NULL
Gy	NULL
Poor	NULL
Dead	NULL
,	NULL
10	NULL
mo	NULL
5	NULL
46	NULL
M	NULL
Tongue	NULL
TNM	NULL
,	NULL
I	NULL
wWDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
``	NULL
NED	NULL
,	NULL
15	NULL
mo	NULL
6	NULL
68	NULL
M	NULL
Tongue	NULL
T	NULL
;	NULL
NoMo	NULL
II	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Poor	NULL
Dead	NULL
,	NULL
6	NULL
mo	NULL
7	NULL
66	NULL
M	NULL
Tongue	NULL
T	NULL
;	NULL
NoMo	NULL
II	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
NED	NULL
,	NULL
25	NULL
mo	NULL
8	NULL
80	NULL
M	NULL
Tongue	NULL
T	NULL
;	NULL
NoM	NULL
II	NULL
wWDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
NED	NULL
,	NULL
16	NULL
mo	NULL
9	NULL
62	NULL
M	NULL
Tongue	NULL
T	NULL
;	NULL
NoM	NULL
I	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
NED	NULL
,	NULL
15	NULL
mo	NULL
10	NULL
69	NULL
M	NULL
Tongue	NULL
T	NULL
;	NULL
NoM	NULL
II	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
NED	NULL
,	NULL
19	NULL
mo	NULL
11	NULL
66	NULL
M	NULL
Oral	NULL
floor	NULL
T	NULL
,	NULL
N	NULL
,	NULL
M	NULL
,	NULL
,	NULL
IV	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
30	NULL
Gy	NULL
Poor	NULL
Dead	NULL
,	NULL
9	NULL
mo	NULL
12	NULL
68	NULL
M	NULL
Oral	NULL
floor	NULL
T	NULL
,	NULL
N	NULL
,	NULL
M	NULL
,	NULL
IV	NULL
PDSCC	NULL
``	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
NED	NULL
,	NULL
23	NULL
mo	NULL
13	NULL
41	NULL
M	NULL
Oral	NULL
floor	NULL
II	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
NED	NULL
,	NULL
20	NULL
mo	NULL
14	NULL
68	NULL
F	NULL
Buccal	NULL
mucosa	NULL
__	NULL
T	NULL
;	NULL
N	NULL
;	NULL
M	NULL
,	NULL
IV	NULL
wDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
+	NULL
40	NULL
Gy	NULL
Poor	NULL
Dead	NULL
,	NULL
10	NULL
mo	NULL
15	NULL
62	NULL
M	NULL
Oropharynx	NULL
IV	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Remarkable	NULL
NED	NULL
,	NULL
25	NULL
mo	NULL
16	NULL
54	NULL
M	NULL
Oropharynx	NULL
TaN	NULL
M	NULL
,	NULL
IV	NULL
WDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
+	NULL
40	NULL
Gy	NULL
Effective	NULL
NED	NULL
,	NULL
13	NULL
mo	NULL
17	NULL
48	NULL
M	NULL
Oropharynx	NULL
T	NULL
,	NULL
IV	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
+	NULL
30	NULL
Gy	NULL
Poor	NULL
Dead	NULL
,	NULL
12	NULL
mo	NULL
18	NULL
67	NULL
M	NULL
Oropharynx	NULL
T	NULL
,	NULL
N	NULL
,	NULL
M	NULL
,	NULL
IV	NULL
wWDSCC	NULL
30	NULL
Gy	NULL
+	NULL
30	NULL
Gy	NULL
Poor	NULL
NED	NULL
,	NULL
24	NULL
mo	NULL
19	NULL
59	NULL
M	NULL
Oropharynx	NULL
IV	NULL
wWDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
NED	NULL
,	NULL
21	NULL
mo	NULL
20	NULL
52	NULL
M	NULL
Oropharynx	NULL
T	NULL
;	NULL
,	NULL
N	NULL
,	NULL
M	NULL
,	NULL
IV	NULL
MDSCC	NULL
60	NULL
Gy	NULL
Effective	NULL
Dead	NULL
,	NULL
5	NULL
mo	NULL
21	NULL
75	NULL
M	NULL
Oropharynx	NULL
TN	NULL
,	NULL
M	NULL
,	NULL
II	NULL
WDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
NED	NULL
,	NULL
20	NULL
mo	NULL
22	NULL
71	NULL
M	NULL
Oropharynx	NULL
T	NULL
;	NULL
,	NULL
N	NULL
,	NULL
M	NULL
,	NULL
II	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
30	NULL
Gy	NULL
Poor	NULL
Dead	NULL
,	NULL
20	NULL
mo	NULL
23	NULL
49	NULL
M	NULL
Oropharynx	NULL
T	NULL
;	NULL
NoMo	NULL
II	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
NED	NULL
,	NULL
18	NULL
mo	NULL
24	NULL
61	NULL
M	NULL
Oropharynx	NULL
T	NULL
;	NULL
NoMo	NULL
II	NULL
MDSCC	NULL
30	NULL
Gy	NULL
+	NULL
op	NULL
Poor	NULL
Dead	NULL
,	NULL
24	NULL
mo	NULL
25	NULL
61	NULL
M	NULL
Maxillary	NULL
T	NULL
,	NULL
N3M	NULL
,	NULL
IV	NULL
WDSCC	NULL
50	NULL
Gy	NULL
+	NULL
op	NULL
Poor	NULL
NED	NULL
,	NULL
21	NULL
mo	NULL
26	NULL
80	NULL
M	NULL
Maxillary	NULL
T	NULL
;	NULL
NoMo	NULL
IV	NULL
wWDSCC	NULL
40	NULL
Gy	NULL
+	NULL
op	NULL
Effective	NULL
Dead	NULL
,	NULL
7	NULL
mo	NULL
27	NULL
67	NULL
M	NULL
Maxillary	NULL
T	NULL
;	NULL
NoMq	NULL
IMI	NULL
MDSCC	NULL
50	NULL
Gy	NULL
+	NULL
op	NULL
Poor	NULL
Dead	NULL
,	NULL
17	NULL
mo	NULL
``	NULL
TNM	NULL
,	NULL
tumor-node-metastastis	NULL
(	NULL
Union	NULL
International	NULL
Contre	NULL
Cancer	NULL
classification	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

``	NULL
WDSCC	NULL
,	NULL
well-differentiated	NULL
squamous	NULL
cell	NULL
carcinoma	NULL
.	NULL

©	NULL
Op	NULL
,	NULL
operation	NULL
.	NULL

``	NULL
Poor	NULL
,	NULL
viable	NULL
residual	NULL
cancer	NULL
cells	NULL
.	NULL

NED	NULL
,	NULL
no	NULL
evidence	NULL
of	NULL
disease	NULL
.	NULL

/	NULL
MDSCC	NULL
,	NULL
moderately	NULL
differentiated	NULL
squamous	NULL
cell	NULL
carcinoma	NULL
.	NULL

®	NULL
Effective	NULL
,	NULL
degenerated	NULL
cancer	NULL
cells	NULL
.	NULL

``	NULL
PDSCC	NULL
,	NULL
poorly	NULL
differentiated	NULL
squamous	NULL
cell	NULL
carcinoma	NULL
.	NULL
'	NULL

Remarkable	NULL
,	NULL
disappearance	NULL
of	NULL
cancer	NULL
cells	NULL
.	NULL

Table	NULL
2	NULL
C-fos	NULL
expression	NULL
in	NULL
cancer	NULL
cells	NULL
and	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
before	NULL
radiotherapy	NULL
and	NULL
at	NULL
cumulative	NULL
doses	NULL
of	NULL
4	NULL
,	NULL
10	NULL
,	NULL
and	NULL
20	NULL
Gy	NULL
of	NULL
radiation	NULL
therapy	NULL
Expression	NULL
of	NULL
c-fos	NULL
in	NULL
cancer	NULL
cells	NULL
Expression	NULL
of	NULL
c-fos	NULL
in	NULL
lymphocytes	NULL
Case	NULL
0	NULL
Gy	NULL
4	NULL
Gy	NULL
10	NULL
Gy	NULL
20	NULL
Gy	NULL
0	NULL
Gy	NULL
4	NULL
Gy	NULL
10	NULL
Gy	NULL
20	NULL
Gy	NULL
1	NULL
-	NULL
-	NULL
-	NULL
-	NULL
None	NULL
None	NULL
None	NULL
None	NULL
--	NULL
-	NULL
-	NULL
NT	NULL
``	NULL
None	NULL
Slight	NULL
Slight	NULL
NT	NULL
3	NULL
-	NULL
-	NULL
-	NULL
-	NULL
None	NULL
None	NULL
None	NULL
None	NULL
4	NULL
-	NULL
NT	NULL
-	NULL
-	NULL
Slight	NULL
NT	NULL
None	NULL
None	NULL
5	NULL
-	NULL
-	NULL
NT	NULL
NT	NULL
None	NULL
None	NULL
NT	NULL
NT	NULL
6	NULL
-	NULL
-	NULL
-	NULL
-	NULL
Slight	NULL
Slight	NULL
Slight	NULL
Slight	NULL
7	NULL
NT	NULL
-	NULL
-	NULL
-	NULL
NT	NULL
None	NULL
Slight	NULL
Slight	NULL
8	NULL
+	NULL
+	NULL
-	NULL
-	NULL
Moderate	NULL
Remarkable	NULL
Moderate	NULL
Slight	NULL
9	NULL
-	NULL
+	NULL
-	NULL
-	NULL
Moderate	NULL
Remarkable	NULL
Slight	NULL
Slight	NULL
10	NULL
-	NULL
-	NULL
-	NULL
-	NULL
Slight	NULL
Slight	NULL
Slight	NULL
None	NULL
11	NULL
-	NULL
NT	NULL
-	NULL
-	NULL
None	NULL
NT	NULL
None	NULL
None	NULL
12	NULL
-	NULL
-	NULL
-	NULL
-	NULL
Slight	NULL
Slight	NULL
Slight	NULL
Slight	NULL
13	NULL
~-	NULL
-	NULL
-	NULL
-	NULL
Slight	NULL
Moderate	NULL
Slight	NULL
Slight	NULL
14	NULL
-	NULL
-	NULL
-	NULL
-	NULL
Slight	NULL
Slight	NULL
Slight	NULL
Slight	NULL
15	NULL
-	NULL
-	NULL
-	NULL
-	NULL
Slight	NULL
Moderate	NULL
Slight	NULL
None	NULL
16	NULL
-	NULL
-	NULL
NT	NULL
NT	NULL
Slight	NULL
Slight	NULL
NT	NULL
NT	NULL
17	NULL
~-	NULL
-	NULL
-	NULL
NT	NULL
None	NULL
Slight	NULL
Slight	NULL
NT	NULL
18	NULL
-	NULL
-	NULL
-	NULL
-	NULL
None	NULL
None	NULL
None	NULL
None	NULL
19	NULL
-	NULL
-	NULL
NT	NULL
NT	NULL
Slight	NULL
Moderate	NULL
NT	NULL
NT	NULL
20	NULL
-	NULL
-	NULL
NT	NULL
-	NULL
Slight	NULL
None	NULL
NT	NULL
None	NULL
21	NULL
NT	NULL
+	NULL
+	NULL
NT	NULL
NT	NULL
Remarkable	NULL
NS	NULL
``	NULL
NT	NULL
22	NULL
-	NULL
NT	NULL
-	NULL
-	NULL
Slight	NULL
NT	NULL
Slight	NULL
Slight	NULL
23	NULL
-	NULL
-	NULL
-	NULL
~-	NULL
Slight	NULL
Moderate	NULL
Slight	NULL
None	NULL
24	NULL
-	NULL
-	NULL
NT	NULL
NT	NULL
Slight	NULL
Slight	NULL
NT	NULL
NT	NULL
25	NULL
-	NULL
-	NULL
-	NULL
-	NULL
None	NULL
None	NULL
None	NULL
None	NULL
26	NULL
-	NULL
-	NULL
-	NULL
-	NULL
Slight	NULL
Slight	NULL
Slight	NULL
None	NULL
27	NULL
-	NULL
-	NULL
-	NULL
-	NULL
Slight	NULL
Slight	NULL
Slight	NULL
None	NULL
``	NULL
NT	NULL
,	NULL
not	NULL
tested	NULL
.	NULL

*	NULL
NS	NULL
,	NULL
non-specific	NULL
staining	NULL
possibly	NULL
due	NULL
to	NULL
endogenous	NULL
peroxidase	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1997	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Clinical	NULL
Cancer	NULL
Research	NULL
2303	NULL
Fig	NULL
.	NULL

1	NULL
-	NULL
Photomicrographs	NULL
of	NULL
the	NULL
tumor	NULL
tissues	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
tongue	NULL
cancer	NULL
(	NULL
case	NULL
9	NULL
)	NULL
.	NULL

At	NULL
pretreatment	NULL
,	NULL
the	NULL
degree	NULL
of	NULL
infiltration	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
into	NULL
tumor	NULL
tissue	NULL
was	NULL
moderate	NULL
,	NULL
but	NULL
at	NULL
a	NULL
4-Gy	NULL
cumulative	NULL
dose	NULL
of	NULL
irradiation	NULL
,	NULL
the	NULL
degree	NULL
of	NULL
infiltration	NULL
was	NULL
remarkable	NULL
(	NULL
magnification	NULL
,	NULL
xX200	NULL
)	NULL
.	NULL

Table	NULL
3	NULL
-	NULL
Statistical	NULL
analysis	NULL
of	NULL
grades	NULL
of	NULL
infiltration	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
into	NULL
tumor	NULL
tissue	NULL
at	NULL
4	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
(	NULL
x	NULL
?	NULL

test	NULL
,	NULL
moderate	NULL
and	NULL
remarkable	NULL
versus	NULL
none	NULL
and	NULL
slight	NULL
)	NULL
Characteristic	NULL
Probability	NULL
Age	NULL
:	NULL
>	NULL
60	NULL
versus	NULL
<	NULL
60	NULL
yr	NULL
NS	NULL
``	NULL
Site	NULL
:	NULL
oral	NULL
cavity	NULL
and	NULL
maxillary	NULL
sinus	NULL
NS	NULL
versus	NULL
oropharynx	NULL
Stages	NULL
II	NULL
and	NULL
III	NULL
versus	NULL
stage	NULL
IV	NULL
NS	NULL
Histology	NULL
:	NULL
WD	NULL
``	NULL
versus	NULL
MD®	NULL
and	NULL
PDC	NULL
NS	NULL
Effect	NULL
:	NULL
remarkable	NULL
and	NULL
effective	NULL
versus	NULL
poor	NULL
P	NULL
<	NULL
0.025	NULL
Prognosis	NULL
:	NULL
dead	NULL
versus	NULL
NED®	NULL
P	NULL
<	NULL
0.05	NULL
``	NULL
NS	NULL
,	NULL
not	NULL
significant	NULL
.	NULL

``	NULL
WD	NULL
,	NULL
well	NULL
differentiated	NULL
.	NULL

©	NULL
MD	NULL
,	NULL
moderately	NULL
differentiated	NULL
.	NULL

``	NULL
PD	NULL
,	NULL
poorly	NULL
differentiated	NULL
.	NULL

©	NULL
NED	NULL
,	NULL
no	NULL
evidence	NULL
of	NULL
disease	NULL
.	NULL

patients	NULL
'	NULL
informed	NULL
consent	NULL
,	NULL
pieces	NULL
of	NULL
approximately	NULL
0.3	NULL
X	NULL
0.3	NULL
x	NULL
0.3	NULL
cm	NULL
were	NULL
cut	NULL
from	NULL
obviously	NULL
viable	NULL
portions	NULL
of	NULL
the	NULL
tumors	NULL
before	NULL
and	NULL
after	NULL
the	NULL
delivery	NULL
of	NULL
4	NULL
,	NULL
10	NULL
,	NULL
and	NULL
20	NULL
Gy	NULL
(	NULL
cumulative	NULL
doses	NULL
)	NULL
of	NULL
irradiation	NULL
.	NULL

All	NULL
of	NULL
the	NULL
tumors	NULL
were	NULL
histopathologically	NULL
diagnosed	NULL
as	NULL
squamous	NULL
cell	NULL
carcinomas	NULL
.	NULL

Samples	NULL
from	NULL
these	NULL
tissue	NULL
specimens	NULL
were	NULL
immediately	NULL
stored	NULL
in	NULL
liquid	NULL
nitrogen	NULL
and	NULL
subsequently	NULL
cut	NULL
into	NULL
6-jum-thick	NULL
serial	NULL
sections	NULL
in	NULL
the	NULL
cryostat	NULL
.	NULL

These	NULL
sections	NULL
were	NULL
immunohis-tochemically	NULL
stained	NULL
by	NULL
the	NULL
streptoavidin-biotin	NULL
peroxidase	NULL
method	NULL
using	NULL
a	NULL
Histofine	NULL
SAB-PO	NULL
kit	NULL
(	NULL
Nichirei	NULL
Co.	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
according	NULL
to	NULL
the	NULL
instruction	NULL
manual	NULL
.	NULL

A	NULL
monoclonal	NULL
antibody	NULL
against	NULL
c-fos	NULL
(	NULL
clone	NULL
NCL-Fos	NULL
;	NULL
IgM	NULL
fraction	NULL
of	NULL
the	NULL
mouse	NULL
monoclonal	NULL
antibody	NULL
)	NULL
was	NULL
also	NULL
used	NULL
.	NULL

The	NULL
antibody	NULL
was	NULL
purchased	NULL
from	NULL
Medac	NULL
Diagnostika	NULL
Co.	NULL
(	NULL
Hamburg	NULL
,	NULL
Germany	NULL
;	NULL
Refs	NULL
.	NULL

7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

The	NULL
procedure	NULL
has	NULL
been	NULL
described	NULL
elsewhere	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

The	NULL
serial	NULL
sections	NULL
were	NULL
also	NULL
similarly	NULL
incubated	NULL
with	NULL
mouse	NULL
gamma	NULL
globulin	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
instead	NULL
of	NULL
the	NULL
anti-c-fos	NULL
monoclonal	NULL
antibody	NULL
and	NULL
without	NULL
the	NULL
primary	NULL
antibody	NULL
to	NULL
exclude	NULL
nonspecific	NULL
staining	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
anti-c-fos	NULL
has	NULL
been	NULL
examined	NULL
previously	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Irradiation	NULL
was	NULL
administered	NULL
with	NULL
4-MV	NULL
X-rays	NULL
on	NULL
an	NULL
ML-15MDX	NULL
linear	NULL
accelerator	NULL
(	NULL
Mitsubishi	NULL
Electric	NULL
Co.	NULL
,	NULL
Ltd.	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

Treatments	NULL
were	NULL
performed	NULL
five	NULL
times	NULL
a	NULL
week	NULL
,	NULL
with	NULL
a	NULL
daily	NULL
dosage	NULL
of	NULL
2	NULL
Gy	NULL
.	NULL

The	NULL
grade	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
c-fos	NULL
protein	NULL
in	NULL
the	NULL
tumor	NULL
cells	NULL
was	NULL
evaluated	NULL
according	NULL
to	NULL
the	NULL
following	NULL
standards	NULL
:	NULL
0	NULL
%	NULL
,	NULL
-	NULL
;	NULL
<	NULL
10	NULL
%	NULL
,	NULL
+	NULL
;	NULL
10-50	NULL
%	NULL
,	NULL
++	NULL
;	NULL
>	NULL
50	NULL
%	NULL
,	NULL
+++	NULL
.	NULL

The	NULL
grade	NULL
was	NULL
estimated	NULL
by	NULL
the	NULL
percentages	NULL
of	NULL
c-fos-positive	NULL
tumor	NULL
cells	NULL
on	NULL
five	NULL
X200	NULL
color	NULL
photographs	NULL
.	NULL

The	NULL
grade	NULL
of	NULL
infiltration	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
into	NULL
the	NULL
tumor	NULL
tissue	NULL
was	NULL
evaluated	NULL
according	NULL
to	NULL
the	NULL
following	NULL
standards	NULL
,	NULL
based	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1997	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

2304	NULL
c-fos	NULL
Expression	NULL
during	NULL
Radiation	NULL
Therapy	NULL
Tongue	NULL
ca	NULL
.	NULL

Fig	NULL
.	NULL

2	NULL
Photomicrographs	NULL
of	NULL
the	NULL
tumor	NULL
tissues	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
tongue	NULL
cancer	NULL
(	NULL
case	NULL
8	NULL
)	NULL
.	NULL

At	NULL
pretreatment	NULL
,	NULL
the	NULL
degree	NULL
of	NULL
infiltration	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
into	NULL
tumor	NULL
tissue	NULL
was	NULL
moderate	NULL
,	NULL
but	NULL
at	NULL
a	NULL
4-Gy	NULL
cumulative	NULL
dose	NULL
of	NULL
irradiation	NULL
,	NULL
the	NULL
degree	NULL
of	NULL
infiltration	NULL
was	NULL
remarkable	NULL
(	NULL
magnification	NULL
,	NULL
x200	NULL
)	NULL
.	NULL

on	NULL
the	NULL
numbers	NULL
of	NULL
the	NULL
cells	NULL
observed	NULL
on	NULL
five	NULL
X200	NULL
color	NULL
photographs	NULL
(	NULL
11	NULL
)	NULL
:	NULL
none	NULL
,	NULL
0	NULL
;	NULL
slight	NULL
,	NULL
<	NULL
100	NULL
;	NULL
moderate	NULL
,	NULL
100-500	NULL
;	NULL
remarkable	NULL
,	NULL
>	NULL
500	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
the	NULL
immunohistochemical	NULL
findings	NULL
and	NULL
the	NULL
therapeutic	NULL
effect	NULL
of	NULL
cumulative	NULL
doses	NULL
of	NULL
20	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
was	NULL
examined	NULL
on	NULL
corresponding	NULL
H	NULL
&	NULL
E-stained	NULL
sections	NULL
.	NULL

RESULTS	NULL
Before	NULL
and	NULL
during	NULL
radiation	NULL
therapy	NULL
,	NULL
none	NULL
of	NULL
the	NULL
tumor	NULL
tissues	NULL
showed	NULL
staining	NULL
grades	NULL
of	NULL
++	NULL
or	NULL
+++	NULL
of	NULL
c-fos	NULL
expres-sion	NULL
.	NULL

Three	NULL
of	NULL
the	NULL
patients	NULL
showed	NULL
a	NULL
slight	NULL
expression	NULL
of	NULL
c-fos	NULL
in	NULL
their	NULL
tumor	NULL
cells	NULL
before	NULL
and/or	NULL
at	NULL
4	NULL
or	NULL
10	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
,	NULL
and	NULL
their	NULL
tumors	NULL
showed	NULL
high	NULL
radiosensitivity	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Despite	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
c-fos	NULL
expression	NULL
in	NULL
the	NULL
tumor	NULL
cells	NULL
,	NULL
the	NULL
degree	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
infiltrating	NULL
tumor	NULL
tissues	NULL
was	NULL
significantly	NULL
increased	NULL
at	NULL
4	NULL
Gy	NULL
compared	NULL
with	NULL
that	NULL
before	NULL
radiotherapy	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
,	NULL
x*	NULL
test	NULL
)	NULL
.	NULL

With	NULL
regard	NULL
to	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
,	NULL
the	NULL
rates	NULL
of	NULL
tumor	NULL
specimens	NULL
of	NULL
moderate	NULL
or	NULL
remarkable	NULL
grades	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
were	NULL
8.0	NULL
(	NULL
2	NULL
of	NULL
25	NULL
)	NULL
,	NULL
29.2	NULL
(	NULL
7	NULL
of	NULL
24	NULL
)	NULL
,	NULL
4.8	NULL
(	NULL
1	NULL
of	NULL
21	NULL
)	NULL
,	NULL
and	NULL
0	NULL
%	NULL
(	NULL
0	NULL
of	NULL
20	NULL
)	NULL
before	NULL
radiation	NULL
therapy	NULL
and	NULL
at	NULL
cumulative	NULL
doses	NULL
of	NULL
4	NULL
,	NULL
10	NULL
,	NULL
and	NULL
20	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
,	NULL
respectively	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Patients	NULL
showing	NULL
moderate	NULL
or	NULL
remarkable	NULL
grades	NULL
of	NULL
infil-	NULL
tration	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
into	NULL
their	NULL
tumor	NULL
tissues	NULL
at	NULL
4	NULL
Gy	NULL
responded	NULL
significantly	NULL
well	NULL
to	NULL
radiation	NULL
therapy	NULL
(	NULL
P	NULL
<	NULL
0.025	NULL
,	NULL
X2	NULL
test	NULL
)	NULL
and	NULL
took	NULL
a	NULL
favorable	NULL
clinical	NULL
course	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
,	NULL
x2	NULL
test	NULL
)	NULL
compared	NULL
to	NULL
other	NULL
patients	NULL
with	NULL
none	NULL
or	NULL
slight	NULL
grades	NULL
of	NULL
infiltration	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
shows	NULL
photomicrographs	NULL
of	NULL
the	NULL
tumor	NULL
tissues	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
tongue	NULL
cancer	NULL
(	NULL
case	NULL
9	NULL
)	NULL
with	NULL
a	NULL
remarkable	NULL
infiltration	NULL
of	NULL
the	NULL
c-fos-positive	NULL
lymphocytes	NULL
into	NULL
tumor	NULL
tissues	NULL
at	NULL
4	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
another	NULL
photomicrograph	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
tongue	NULL
cancer	NULL
(	NULL
case	NULL
8	NULL
)	NULL
shows	NULL
a	NULL
remarkable	NULL
degree	NULL
of	NULL
infiltration	NULL
by	NULL
the	NULL
c-fos-positive	NULL
lymphocytes	NULL
at	NULL
4	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
the	NULL
photomicrographs	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
oropharyngeal	NULL
cancer	NULL
(	NULL
case	NULL
21	NULL
)	NULL
also	NULL
show	NULL
a	NULL
remarkable	NULL
degree	NULL
of	NULL
infiltration	NULL
by	NULL
the	NULL
c-fos-positive	NULL
lymphocytes	NULL
and	NULL
a	NULL
slight	NULL
expression	NULL
of	NULL
c-fos	NULL
in	NULL
the	NULL
tumor	NULL
cells	NULL
at	NULL
4	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
.	NULL

At	NULL
10	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
,	NULL
most	NULL
of	NULL
the	NULL
tumor	NULL
cells	NULL
and	NULL
the	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
show	NULL
signs	NULL
of	NULL
pyknosis	NULL
,	NULL
which	NULL
is	NULL
considered	NULL
to	NULL
be	NULL
a	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
most	NULL
of	NULL
the	NULL
c-fos-positive	NULL
lymphocytes	NULL
are	NULL
CD4	NULL
positive	NULL
and	NULL
CD8	NULL
negative	NULL
(	NULL
case	NULL
2	NULL
)	NULL
,	NULL
and	NULL
these	NULL
lymphocytes	NULL
are	NULL
considered	NULL
to	NULL
be	NULL
activated	NULL
helper/inducer	NULL
T	NULL
lymphocytes	NULL
,	NULL
not	NULL
suppressor/cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1997	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Clinical	NULL
Cancer	NULL
Research	NULL
2305	NULL
fos	NULL
4	NULL
Gy	NULL
10	NULL
Gy	NULL
Fig	NULL
.	NULL

3	NULL
Photomicrographs	NULL
of	NULL
the	NULL
tumor	NULL
tissues	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
oropharyngeal	NULL
cancer	NULL
(	NULL
case	NULL
21	NULL
)	NULL
.	NULL

At	NULL
a	NULL
4-Gy	NULL
cumulative	NULL
dose	NULL
of	NULL
irradiation	NULL
,	NULL
the	NULL
infiltration	NULL
of	NULL
the	NULL
c-fos-positive	NULL
lymphocytes	NULL
into	NULL
tumor	NULL
tissues	NULL
was	NULL
remarkable	NULL
,	NULL
and	NULL
the	NULL
tumor	NULL
cells	NULL
showed	NULL
a	NULL
slight	NULL
expression	NULL
of	NULL
c-fos	NULL
.	NULL

At	NULL
a	NULL
10-Gy	NULL
cumulative	NULL
dose	NULL
of	NULL
irradiation	NULL
,	NULL
most	NULL
of	NULL
the	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
and	NULL
the	NULL
tumor	NULL
cells	NULL
showed	NULL
pyknosis	NULL
on	NULL
their	NULL
H	NULL
&	NULL
E-stained	NULL
sections	NULL
,	NULL
which	NULL
was	NULL
considered	NULL
to	NULL
be	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
,	NULL
and	NULL
these	NULL
cells	NULL
showed	NULL
nonspecific	NULL
staining	NULL
,	NULL
possibly	NULL
due	NULL
to	NULL
endogenous	NULL
peroxidase	NULL
(	NULL
magnification	NULL
,	NULL
x200	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
expression	NULL
of	NULL
c-fos	NULL
mRNA	NULL
in	NULL
experimental	NULL
cell	NULL
lines	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
augmented	NULL
by	NULL
many	NULL
types	NULL
of	NULL
stresses	NULL
,	NULL
including	NULL
UV	NULL
irradiation	NULL
,	NULL
ionizing	NULL
radiation	NULL
,	NULL
and	NULL
heat	NULL
(	NULL
2-4	NULL
,	NULL
12	NULL
)	NULL
.	NULL

There	NULL
are	NULL
still	NULL
a	NULL
few	NULL
reports	NULL
,	NULL
however	NULL
,	NULL
of	NULL
c-fos	NULL
expression	NULL
in	NULL
tumor	NULL
tissue	NULL
.	NULL

In	NULL
most	NULL
osteosarcoma	NULL
cells	NULL
and	NULL
in	NULL
some	NULL
types	NULL
of	NULL
leukemia	NULL
cell	NULL
lines	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
c-fos	NULL
mRNA	NULL
has	NULL
been	NULL
identified	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
possible	NULL
involvement	NULL
of	NULL
c-fos	NULL
expression	NULL
in	NULL
tumor	NULL
cells	NULL
in	NULL
the	NULL
proliferation	NULL
mechanisms	NULL
of	NULL
these	NULL
tumors	NULL
has	NULL
been	NULL
speculated	NULL
.	NULL

Because	NULL
the	NULL
half-life	NULL
of	NULL
c-fos	NULL
is	NULL
relatively	NULL
short	NULL
(	NULL
approxi-mately	NULL
30	NULL
min	NULL
)	NULL
,	NULL
the	NULL
immunohistochemical	NULL
detection	NULL
of	NULL
c-fos	NULL
is	NULL
quite	NULL
difficult	NULL
,	NULL
and	NULL
there	NULL
have	NULL
been	NULL
few	NULL
reports	NULL
of	NULL
c-fos	NULL
expression	NULL
in	NULL
tumor	NULL
tissues	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Only	NULL
one	NULL
article	NULL
has	NULL
reported	NULL
an	NULL
alteration	NULL
in	NULL
c-fos	NULL
expression	NULL
after	NULL
the	NULL
irradiation	NULL
of	NULL
solid	NULL
tumor	NULL
tissues	NULL
(	NULL
5	NULL
)	NULL
.	NULL

In	NULL
the	NULL
article	NULL
,	NULL
Miura	NULL
et	NULL
al	NULL
.	NULL

(	NULL
5	NULL
)	NULL
reported	NULL
that	NULL
the	NULL
rate	NULL
of	NULL
c-fos	NULL
expression	NULL
in	NULL
tumor	NULL
tissues	NULL
of	NULL
the	NULL
head	NULL
and	NULL
neck	NULL
was	NULL
relatively	NULL
low	NULL
and	NULL
seemed	NULL
to	NULL
be	NULL
unaffected	NULL
by	NULL
radiation	NULL
therapy	NULL
.	NULL

Their	NULL
specimens	NULL
,	NULL
however	NULL
,	NULL
were	NULL
obtained	NULL
only	NULL
before	NULL
and	NULL
after	NULL
radiation	NULL
therapy	NULL
.	NULL

In	NULL
a	NULL
previous	NULL
paper	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
sequential	NULL
alteration	NULL
of	NULL
proto-oncogene	NULL
mRNA	NULL
expression	NULL
in	NULL
the	NULL
liver	NULL
,	NULL
spleen	NULL
,	NULL
kid	NULL
ney	NULL
,	NULL
and	NULL
brain	NULL
of	NULL
mice	NULL
after	NULL
whole-body	NULL
irradiation	NULL
of	NULL
7	NULL
Gy	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
mRNAs	NULL
examined	NULL
in	NULL
the	NULL
study	NULL
were	NULL
fas	NULL
,	NULL
c-fos	NULL
,	NULL
c-myc	NULL
,	NULL
bel-2	NULL
,	NULL
and	NULL
p53	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
decreased	NULL
2	NULL
h	NULL
after	NULL
irradiation	NULL
and	NULL
increased	NULL
remarkably	NULL
thereafter	NULL
in	NULL
the	NULL
spleen	NULL
,	NULL
possibly	NULL
due	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
splenic	NULL
lymphocytes	NULL
.	NULL

In	NULL
the	NULL
other	NULL
organs	NULL
that	NULL
were	NULL
examined	NULL
,	NULL
such	NULL
an	NULL
increase	NULL
in	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
was	NULL
not	NULL
observed	NULL
.	NULL

It	NULL
was	NULL
therefore	NULL
considered	NULL
to	NULL
be	NULL
important	NULL
to	NULL
examine	NULL
the	NULL
expression	NULL
of	NULL
c-fos	NULL
in	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
induced	NULL
by	NULL
low	NULL
doses	NULL
of	NULL
radiotherapy	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
we	NULL
have	NULL
attempted	NULL
to	NULL
measure	NULL
the	NULL
grade	NULL
of	NULL
c-fos	NULL
expression	NULL
in	NULL
tumor	NULL
cells	NULL
and	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
of	NULL
the	NULL
head	NULL
and	NULL
neck	NULL
before	NULL
radiation	NULL
therapy	NULL
and	NULL
serially	NULL
during	NULL
radiotherapy	NULL
.	NULL

Because	NULL
of	NULL
its	NULL
relatively	NULL
short	NULL
half-life	NULL
,	NULL
and	NULL
because	NULL
it	NULL
is	NULL
expressed	NULL
immediately	NULL
after	NULL
several	NULL
kinds	NULL
of	NULL
extracellular	NULL
stimuli	NULL
in	NULL
its	NULL
role	NULL
as	NULL
a	NULL
signal	NULL
transduction	NULL
mediator	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
c-fos	NULL
must	NULL
be	NULL
detected	NULL
as	NULL
soon	NULL
as	NULL
possible	NULL
after	NULL
the	NULL
stimuli	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
detection	NULL
of	NULL
c-fos	NULL
expression	NULL
in	NULL
tumor	NULL
tissues	NULL
after	NULL
radiation	NULL
therapy	NULL
has	NULL
given	NULL
no	NULL
meaningful	NULL
results	NULL
.	NULL

As	NULL
shown	NULL
by	NULL
our	NULL
results	NULL
,	NULL
c-fos	NULL
expression	NULL
is	NULL
observed	NULL
mostly	NULL
in	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
and	NULL
is	NULL
rarely	NULL
observed	NULL
Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1997	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

2306	NULL
c-fos	NULL
Expression	NULL
during	NULL
Radiation	NULL
Therapy	NULL
Tongue	NULL
ca	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
-	NULL
At	NULL
cumulative	NULL
doses	NULL
of	NULL
4	NULL
Gy	NULL
of	NULL
radiotherapy	NULL
,	NULL
the	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
showed	NULL
positive	NULL
staining	NULL
for	NULL
both	NULL
anti-c-fos	NULL
and	NULL
anti-CD4	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
negative	NULL
staining	NULL
for	NULL
anti-CD8	NULL
(	NULL
magnification	NULL
,	NULL
X	NULL
200	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
lymphocytes	NULL
are	NULL
considered	NULL
to	NULL
be	NULL
activated	NULL
helper/inducer	NULL
T	NULL
lymphocytes	NULL
.	NULL

in	NULL
tumor	NULL
cells	NULL
at	NULL
low	NULL
doses	NULL
of	NULL
radiation	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
c-fos-positive	NULL
lymphocytes	NULL
infiltrating	NULL
the	NULL
tumor	NULL
tissues	NULL
have	NULL
been	NULL
identified	NULL
as	NULL
CD4	NULL
positive	NULL
and	NULL
CD8	NULL
negative	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
c-fos-positive	NULL
lymphocytes	NULL
are	NULL
considered	NULL
to	NULL
be	NULL
activated	NULL
helper/inducer	NULL
T	NULL
lymphocytes	NULL
,	NULL
which	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
our	NULL
previous	NULL
paper	NULL
as	NULL
a	NULL
possible	NULL
predictor	NULL
of	NULL
a	NULL
favorable	NULL
response	NULL
to	NULL
radiation	NULL
therapy	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

As	NULL
mentioned	NULL
above	NULL
,	NULL
the	NULL
c-fos-positive	NULL
lymphocytes	NULL
are	NULL
induced	NULL
at	NULL
low	NULL
doses	NULL
of	NULL
radiation	NULL
therapy	NULL
and	NULL
disappear	NULL
at	NULL
cumulative	NULL
doses	NULL
of	NULL
20	NULL
Gy	NULL
in	NULL
the	NULL
tumor	NULL
tissues	NULL
of	NULL
head	NULL
and	NULL
neck	NULL
cancer	NULL
patients	NULL
,	NULL
whose	NULL
tumors	NULL
respond	NULL
well	NULL
to	NULL
radiation	NULL
therapy	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
appearance	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
in	NULL
tumor	NULL
tissues	NULL
at	NULL
low	NULL
doses	NULL
of	NULL
radiotherapy	NULL
possibly	NULL
predicts	NULL
a	NULL
favorable	NULL
clinical	NULL
course	NULL
for	NULL
the	NULL
patient	NULL
and	NULL
may	NULL
be	NULL
considered	NULL
as	NULL
an	NULL
independent	NULL
predictor	NULL
for	NULL
radiation	NULL
therapy	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Muller	NULL
,	NULL
R.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
,	NULL
Burckhardt	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Curran	NULL
,	NULL
T.	NULL
Induction	NULL
of	NULL
c-fos	NULL
gene	NULL
and	NULL
protein	NULL
by	NULL
growth	NULL
factors	NULL
precedes	NULL
activation	NULL
of	NULL
c-myc	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
372	NULL
:	NULL
716-720	NULL
,	NULL
1984	NULL
.	NULL

2	NULL
.	NULL

Syljuasen	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
Hong	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
McBride	NULL
,	NULL
W.	NULL
H.	NULL
Apoptosis	NULL
and	NULL
delayed	NULL
expression	NULL
of	NULL
c-jun	NULL
and	NULL
c-fos	NULL
after	NULL
y	NULL
irradiation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Radiat	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
146	NULL
:	NULL
276-282	NULL
,	NULL
1996	NULL
.	NULL

Downloaded	NULL
from	NULL
3	NULL
.	NULL

Prasad	NULL
,	NULL
A.	NULL
V.	NULL
,	NULL
Mohan	NULL
,	NULL
N.	NULL
,	NULL
Chandrasekar	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Meltz	NULL
,	NULL
M.	NULL
L.	NULL
Induction	NULL
of	NULL
transcription	NULL
of	NULL
immediate	NULL
early	NULL
genes	NULL
by	NULL
low-dose	NULL
ionizing	NULL
radiation	NULL
.	NULL

Radiat	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
143	NULL
:	NULL
263-272	NULL
,	NULL
1995	NULL
.	NULL

4	NULL
.	NULL

Schreiber	NULL
,	NULL
M.	NULL
,	NULL
Baumann	NULL
,	NULL
B.	NULL
,	NULL
Cotten	NULL
,	NULL
M.	NULL
,	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Wagner	NULL
,	NULL
E.	NULL
F.	NULL
Fos	NULL
is	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
the	NULL
mammalian	NULL
UV	NULL
response	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
14	NULL
;	NULL
5338-5349	NULL
,	NULL
1995	NULL
.	NULL

5	NULL
.	NULL

Miura	NULL
,	NULL
K.	NULL
,	NULL
Suzuki	NULL
,	NULL
S.	NULL
,	NULL
Tanita	NULL
,	NULL
J.	NULL
,	NULL
Shinkawa	NULL
,	NULL
H.	NULL
,	NULL
Satoh	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Tsuchida	NULL
,	NULL
S.	NULL
Correlated	NULL
expression	NULL
of	NULL
glutathione	NULL
S-transferase-t	NULL
and	NULL
c-Jun	NULL
or	NULL
other	NULL
oncogene	NULL
products	NULL
in	NULL
human	NULL
squamous	NULL
cell	NULL
carcinomas	NULL
of	NULL
the	NULL
head	NULL
and	NULL
neck	NULL
:	NULL
relevance	NULL
to	NULL
relapse	NULL
after	NULL
radiation	NULL
therapy	NULL
.	NULL

Jpn	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
88	NULL
:	NULL
143-151	NULL
,	NULL
1997	NULL
.	NULL

6	NULL
.	NULL

Vrdoljak	NULL
,	NULL
E.	NULL
,	NULL
Borchardt	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
Bill	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Stephens	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
and	NULL
To-filon	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

Influence	NULL
of	NULL
X-rays	NULL
on	NULL
early	NULL
response	NULL
gene	NULL
expression	NULL
in	NULL
rat	NULL
astrocytes	NULL
and	NULL
brain	NULL
tumor	NULL
cell	NULL
lines	NULL
.	NULL

Int	NULL
.	NULL

J.	NULL
Radiat	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
66	NULL
:	NULL
739-746	NULL
,	NULL
1994	NULL
.	NULL

7	NULL
.	NULL

Curran	NULL
,	NULL
T.	NULL
,	NULL
Miller	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Zokas	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
Viral	NULL
and	NULL
cellular	NULL
Fos	NULL
proteins	NULL
:	NULL
a	NULL
comparative	NULL
analysis	NULL
.	NULL

Cell	NULL
,	NULL
36	NULL
:	NULL
259-268	NULL
,	NULL
1984	NULL
.	NULL

8	NULL
,	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
,	NULL
and	NULL
Graham	NULL
,	NULL
W.	NULL
R.	NULL
The	NULL
fos	NULL
oncogene	NULL
.	NULL

Adv	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
49	NULL
:	NULL
29-52	NULL
,	NULL
1987	NULL
.	NULL

9	NULL
.	NULL

Ogawa	NULL
,	NULL
Y.	NULL
,	NULL
Maeda	NULL
,	NULL
T.	NULL
,	NULL
Seguchi	NULL
,	NULL
H.	NULL
,	NULL
Hamada	NULL
,	NULL
F.	NULL
,	NULL
Inomata	NULL
,	NULL
T.	NULL
,	NULL
Yoshida	NULL
,	NULL
S.	NULL
,	NULL
Kishimoto	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Saito	NULL
,	NULL
H.	NULL
Infiltration	NULL
of	NULL
Leu-3a	NULL
+	NULL
3b-positive	NULL
lymphocytes	NULL
and	NULL
expression	NULL
of	NULL
human	NULL
leukocyte	NULL
antigen	NULL
DR	NULL
on	NULL
tumor	NULL
tissue	NULL
induced	NULL
by	NULL
radiation	NULL
therapy	NULL
.	NULL

Oncology	NULL
(	NULL
Basel	NULL
)	NULL
,	NULL
45	NULL
:	NULL
18-20	NULL
,	NULL
1988	NULL
.	NULL

10	NULL
.	NULL

Ogawa	NULL
,	NULL
Y.	NULL
,	NULL
Maeda	NULL
,	NULL
T.	NULL
,	NULL
Seguchi	NULL
,	NULL
H.	NULL
,	NULL
Inomata	NULL
,	NULL
T.	NULL
,	NULL
Yoshida	NULL
,	NULL
S.	NULL
,	NULL
Kishimoto	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Saito	NULL
,	NULL
H.	NULL
Application	NULL
of	NULL
the	NULL
immunohistochemical	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1997	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Clinical	NULL
Cancer	NULL
Research	NULL
2307	NULL
method	NULL
as	NULL
a	NULL
predictive	NULL
assay	NULL
in	NULL
radiotherapy	NULL
of	NULL
squamous	NULL
cell	NULL
carcinoma	NULL
of	NULL
oropharynx	NULL
and	NULL
hypopharynx	NULL
.	NULL

Oncology	NULL
(	NULL
Basel	NULL
)	NULL
.	NULL

47	NULL
:	NULL
155-159	NULL
,	NULL
1990	NULL
.	NULL

11	NULL
.	NULL

Inomata	NULL
,	NULL
T.	NULL
,	NULL
Goodman	NULL
,	NULL
G.	NULL
B..	NULL
Fryer	NULL
,	NULL
C.	NULL
J.	NULL
H..	NULL
Chaplin	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Palcic	NULL
.	NULL

B.	NULL
,	NULL
Lam	NULL
,	NULL
G.	NULL
K.	NULL
Y.	NULL
,	NULL
Nishioka	NULL
,	NULL
A..	NULL
and	NULL
Ogawa	NULL
,	NULL
Y	NULL
.	NULL

Immune	NULL
reaction	NULL
induced	NULL
by	NULL
X-rays	NULL
and	NULL
pions	NULL
and	NULL
its	NULL
stimulation	NULL
by	NULL
schizophyllan	NULL
(	NULL
SPG	NULL
)	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
74	NULL
:	NULL
$	NULL
122-	NULL
$	NULL
125	NULL
,	NULL
1996	NULL
.	NULL

12	NULL
.	NULL

Gubits	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Fairhurst	NULL
,	NULL
J.	NULL
L.	NULL
C-fos	NULL
mRNA	NULL
levels	NULL
are	NULL
increased	NULL
by	NULL
the	NULL
cellular	NULL
stressors	NULL
,	NULL
heat	NULL
shock	NULL
and	NULL
sodium	NULL
arsenite	NULL
.	NULL

Oncogene	NULL
,	NULL
3	NULL
:	NULL
163-168	NULL
,	NULL
1988	NULL
.	NULL

13	NULL
.	NULL

Wu	NULL
,	NULL
J.	NULL
X.	NULL
,	NULL
Carpenter	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Gresens	NULL
,	NULL
C.	NULL
,	NULL
Keh	NULL
,	NULL
R.	NULL
,	NULL
Niman	NULL
,	NULL
H..	NULL
Mortis	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
and	NULL
Mercola	NULL
,	NULL
D.	NULL
The	NULL
proto-oncogene	NULL
c-fos	NULL
is	NULL
over	NULL
expressed	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
human	NULL
osteosarcomas	NULL
.	NULL

Oncogene	NULL
,	NULL
5	NULL
:	NULL
989-1000	NULL
,	NULL
1990	NULL
.	NULL

14	NULL
.	NULL

Tsai	NULL
,	NULL
L-H.	NULL
,	NULL
Nanu	NULL
,	NULL
L.	NULL
,	NULL
Smith	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
and	NULL
Ozanne	NULL
,	NULL
B.	NULL
Overexpression	NULL
of	NULL
c-fos	NULL
in	NULL
a	NULL
human	NULL
pre-B	NULL
cell	NULL
acute	NULL
lymphocytic	NULL
leukemia-derived	NULL
cell	NULL
line	NULL
.	NULL

Oncogene	NULL
,	NULL
6	NULL
:	NULL
81-88	NULL
,	NULL
1991	NULL
.	NULL

15	NULL
.	NULL

Hesketh	NULL
,	NULL
R.	NULL
FOS	NULL
.	NULL

In	NULL
:	NULL
The	NULL
Oncogene	NULL
Handbook	NULL
,	NULL
pp	NULL
.	NULL

178-199	NULL
.	NULL

London	NULL
:	NULL
Academic	NULL
Press	NULL
Limited	NULL
,	NULL
1994	NULL
.	NULL

16	NULL
.	NULL

Ogawa	NULL
,	NULL
Y.	NULL
,	NULL
Saibara	NULL
,	NULL
T.	NULL
,	NULL
Terashima	NULL
,	NULL
M.	NULL
,	NULL
Ono	NULL
,	NULL
M.	NULL
,	NULL
Hamada	NULL
,	NULL
N.	NULL
,	NULL
Nishioka	NULL
,	NULL
A..	NULL
Inomata	NULL
,	NULL
T.	NULL
,	NULL
Onishi	NULL
,	NULL
S.	NULL
,	NULL
Yoshida	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Seguchi	NULL
,	NULL
H.	NULL
Sequential	NULL
alteration	NULL
of	NULL
proto-oncogene	NULL
expression	NULL
in	NULL
liver	NULL
,	NULL
spleen	NULL
,	NULL
kidney	NULL
and	NULL
brain	NULL
of	NULL
mice	NULL
subjected	NULL
to	NULL
whole	NULL
body	NULL
irradiation	NULL
.	NULL

Oncology	NULL
(	NULL
Basel	NULL
)	NULL
,	NULL
53	NULL
:	NULL
412-416	NULL
,	NULL
1996	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1997	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
SX	NULL
Clinical	NULL
Cancer	NULL
Research	NULL
Immunohistochemical	NULL
study	NULL
of	NULL
c-fos-positive	NULL
lymphocytes	NULL
infiltrated	NULL
into	NULL
human	NULL
squamous	NULL
cell	NULL
carcinomas	NULL
of	NULL
the	NULL
head	NULL
and	NULL
neck	NULL
during	NULL
radiation	NULL
therapy	NULL
and	NULL
its	NULL
clinical	NULL
significance	NULL
.	NULL

Y	NULL
Ogawa	NULL
,	NULL
A	NULL
Nishioka	NULL
,	NULL
N	NULL
Hamada	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Clin	NULL
Cancer	NULL
Res	NULL
1997	NULL
;	NULL
3:2301-2307	NULL
.	NULL

Updated	NULL
version	NULL
_	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//clincancerres.aacrjournals.org/content/3/12/2301	NULL
E-mail	NULL
alerts	NULL
_	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

Reprints	NULL
and	NULL
_	NULL
To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Subscriptions	NULL
_	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

Permissions	NULL
_	NULL
To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//clincancerres.aacrjournals.org/content/3/12/2301	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
clincancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1997	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

